Takeda Submits New Drug Application in Japan for Lanadelumab as a Preventive Treatment for Hereditary Angioedema AttacksBusiness Wire • 03/12/21
Takeda's Growth and Emerging Markets Business Unit Aims to Deliver Double-Digit Revenue Growth Over Next Decade1Business Wire • 03/11/21
BioLife Plasma Services Announces Opening of First Plasma Donation Center in New JerseyBusiness Wire • 03/10/21
Takeda to Acquire Maverick Therapeutics to Advance T-Cell Engager Therapies for Solid Tumors and Expand Novel Immuno-Oncology PortfolioBusiness Wire • 03/09/21
Moderna Announces New Drug Application Submitted to Import and Distribute Moderna's COVID-19 Vaccine Candidate in JapanBusiness Wire • 03/05/21
Ovid Shares Rally On Soticlestat Development Pact With Takeda In Rare Epilepsy SyndromesBenzinga • 03/03/21
Takeda Secures Global Rights from Ovid Therapeutics to Develop and Commercialize Soticlestat for the Treatment of Children and Adults with Dravet Syndrome and Lennox-Gastaut SyndromeBusiness Wire • 03/03/21
BioLife Plasma Services Announces Expansion of Plasma Donation Centers Into CaliforniaBusiness Wire • 02/24/21
Takeda Provides Updates on Phase 1/2 Clinical Trials of Novavax' and Moderna's COVID-19 Vaccine Candidates in JapanBusiness Wire • 02/24/21
First non-Japanese CEO of Takeda has set out 2 objectives: to be an R&D-driven firm and to build global scaleBusiness Insider • 02/18/21
Takeda Receives Prestigious EURORDIS 2021 Black Pearl Award for Patient EngagementBusiness Wire • 02/18/21
Takeda's Maribavir Hits Primary Endpoint Goal In Late-Stage Study In Transplant RecipientsBenzinga • 02/12/21
Takeda's Maribavir Phase 3 Clinical Trial Met Primary Endpoint of Superiority to Conventional Antiviral Therapy in Transplant Recipients With Refractory, With or Without Resistance, Cytomegalovirus Infection/DiseaseBusiness Wire • 02/12/21
Takeda Submits New Drug Application to Manufacture and Market Darvadstrocel In Japan for Treatment of Complex Perianal Fistulas in Adult Patients with Crohn's DiseaseBusiness Wire • 02/10/21